Literature DB >> 16321402

Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice.

Dakuan Gao1, Xiang Zhang, Xiaofan Jiang, Yabin Peng, Weidong Huang, Guang Cheng, Lei Song.   

Abstract

Stroke is one of the leading causes of mortality; however, its treatment remains obscure and largely empirical. Since matrix metalloproteinase 9 (MMP-9) has been postulated to be the major contributor of neuronal injury during reperfusion, inhibition of MMP-9 could be a potential approach in maintaining the viability of neurons. Trans-resveratrol (resveratrol), a polyphenolic compound has recently been shown to have neuroprotective activity against cerebral ischemia. Therefore, the aim of the present study was to evaluate the effect of resveratrol on MMP-9 induced by cerebral ischemia-reperfusion in vivo. Male Balb/C mice were treated with resveratrol for 7 days (50 mg/kg, gavage). Thereafter, middle cerebral artery occlusion (MCAo) was performed for 2 h with the help of intraluminal thread. Drug-treated mice showed improvement in necrotic changes in cortex and basal ganglia. Detection of MMP-9 activity and gene expression was performed at various time points after MCAo. The elevated levels of MMP-9 were significantly attenuated in the resveratrol-treated mice as compared to the vehicle MCAo mice. The study suggests that resveratrol has protective effects against acute ischemic stroke, which could be attributed to its property against MMP-9. Thus, resveratrol may be a potential agent for the treatment of neuronal injury associated with stroke.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16321402     DOI: 10.1016/j.lfs.2005.10.030

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  40 in total

Review 1.  Resveratrol neuroprotection in stroke and traumatic CNS injury.

Authors:  Mary S Lopez; Robert J Dempsey; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2015-08-12       Impact factor: 3.921

Review 2.  Dietary flavonoids are neuroprotective through Nrf2-coordinated induction of endogenous cytoprotective proteins.

Authors:  Christopher C Leonardo; Sylvain Doré
Journal:  Nutr Neurosci       Date:  2011-09       Impact factor: 4.994

3.  Effects of hyperbaric oxygen on the expression of claudins after cerebral ischemia-reperfusion in rats.

Authors:  Hong Zhao; Qianru Zhang; Yixue Xue; Xuexin Chen; Randy S Haun
Journal:  Exp Brain Res       Date:  2011-05-31       Impact factor: 1.972

Review 4.  Herbal medicines for ischemic stroke: combating inflammation as therapeutic targets.

Authors:  Yong Gu; Jianping Chen; Jiangang Shen
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-22       Impact factor: 4.147

Review 5.  Targeting extracellular matrix remodeling in disease: Could resveratrol be a potential candidate?

Authors:  Renu Agarwal; Puneet Agarwal
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-23

6.  Resveratrol alleviates nerve injury after cerebral ischemia and reperfusion in mice by inhibiting inflammation and apoptosis.

Authors:  Liqun Fang; Hongmei Gao; Weina Zhang; Wenjie Zhang; Yanan Wang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 7.  Mitochondrial function in hypoxic ischemic injury and influence of aging.

Authors:  P Benson Ham; Raghavan Raju
Journal:  Prog Neurobiol       Date:  2016-06-16       Impact factor: 11.685

Review 8.  Phytochemicals in Ischemic Stroke.

Authors:  Joonki Kim; David Yang-Wei Fann; Raymond Chee Seong Seet; Dong-Gyu Jo; Mark P Mattson; Thiruma V Arumugam
Journal:  Neuromolecular Med       Date:  2016-05-18       Impact factor: 3.843

9.  Mmp-9, a potential target for cerebral ischemic treatment.

Authors:  Xue Dong; Yu-Ning Song; Wei-Guo Liu; Xiu-Li Guo
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

10.  Resveratrol mitigates rat retinal ischemic injury: the roles of matrix metalloproteinase-9, inducible nitric oxide, and heme oxygenase-1.

Authors:  Xiao-Qian Liu; Bing-Jhih Wu; Wynn H T Pan; Xiu-Mei Zhang; Jorn-Hon Liu; Mi-Mi Chen; Fang-Ping Chao; Hsiao-Ming Chao
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-17       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.